Clinical trial NCT02416661: Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease
Official title: Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lysosomal Storage Diseases
Gaucher Disease
Sphingolipidoses
Keywords: Gaucher Disease type 1
Lymphatic Diseases
Lipid Metabolism, Inborn Errors
Lipid Metabolism Disorders
Lipidoses
Lead sponsor: CENTOGENE GmbH Rostock
Sponsor class: INDUSTRY
First posted: 2015-04-15
Enrollment: 299
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Male or female patients aged 6 months or older with genetically confirmed diagnosis of Gaucher disease type 1 without treatment prior to enrollment or no treatment for more than 24 months ago

Brief summary: International, multicenter, epidemiological study to demonstrate the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3

Detailed description: Gaucher disease is an autosomal recessive inherited lysosomal storage disorder. The disease is caused by the hereditary deficiency of the glucocerebrosidase, a lysosomal enzyme that breaks down glucocerebroside into glucose and ceramide.

To date a definitive diagnosis of Gaucher's disease can only be made applying biochemical testing measuring the reduced enzymatic activity of the beta-glucosidase together with genetic confirmation. Since numerous different mutations may be the cause of a particular lysosomal storage disease the sequencing of the entire beta-glucosidase gene is applied in Gaucher's disease in order to confirm the genetic diagnosis.

The use of primary storage molecules as biomarker was assessed for glucosylceramide (Gb1) in plasma of Gaucher's disease patients and compared to the level of Gb1 in healthy individuals.

In order to establish a sensitive and specific biomarker for GD, we compared mass spectra of the plasma of healthy controls and GD patients using HPLC and tandem mass spectrometry. Mass spectra that differed most between patients and controls were analysed in more detail. The resulting biomarker, which was patented in June 2011 (PCT/EP2012/002409), was lyso - Gb1. We identified this compound as a reliable, sensitive and specific biomarker for GD in a cohort of GD patients. Furthermore, in a pilot study we evaluated whether lyso-Gb1 is related to the specific genotypes and is reliable for long-term monitoring of the efficiency of therapy.

The aim this study is therefore to investigate lyso-Gb1 as a long-term prognostic marker in naïve, non-ERT/SRT GD type 1 patients by monitoring over the course of 36 months.

Eligibility criteria: Inclusion Criteria:

* Male or female patients aged 6 months or older
* Patients with genetically confirmed diagnosis of Gaucher disease type 1
* No prior treatment with enzyme replacement therapy or substrate reduction therapy ro no traetment for more than 24 months
* Signed informed consent by parents/legal guardian and patient

Exclusion Criteria:

* Male or female patients being younger than 6 months
* Patients without genetically confirmed diagnosis of Gaucher disease type 1
* Gaucher disease 2 or 3
* Patient is currently undergoing enzyme replacement therapy or substrate reduction therapy
* Missing signed informed consent

Primary outcomes:
measure: Demonstrating the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients
timeFrame: 48 month
Secondary outcomes:
measure: Correlating lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3.
timeFrame: 48 month
Other outcomes:
Locations:
city: Tirana
country: Albania
facility: University Hospital Center Mother Teresa
city: Thessaloniki
country: Greece
facility: Aristotle University of Thessaloniki, Ippokration General Hospital
city: Bangalore
country: India
facility: Centre for Human Genetics
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
city: Rabat
country: Morocco
facility: Children hospital
city: Rabat
country: Morocco
facility: Hopital d'Enfant
city: Lahore
country: Pakistan
facility: The Children's Hospital and the Institute of Child Health
state: Punjab
city: Barcelona
country: Spain
facility: Hospital Universitari de Bellvitge (planta 7.1)
Study officials:
affiliation: CENTOGENE GmbH Rostock
name: Peter Bauer, M.D.
role: STUDY_CHAIR
References:
citation: Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, Eichler S, Bottcher T, Zimran A. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials. Mol Genet Metab. 2017 Sep;122(1-2):113-120. doi: 10.1016/j.ymgme.2017.08.005. Epub 2017 Aug 24.